Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
Abstract
To evaluate the prognostic value of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) with NPM1 mutation (NPM1(mut)).
Beteiligte Forschungseinheiten
Leibniz-HKI-Autor*innen
Identifier
doi: 10.1200/JCO.2011.35.0371
PMID: 21555683